caa a22 4500 477057934 CHVBK 20180405111352.0 cr unu---uuuuu 170330e19960301xx s 000 0 eng 10.1007/BF00195935 doi (NATIONALLICENCE)springer-10.1007/BF00195935 Therapeutic monitoring of nalbuphine: transplacental transfer and estimated pharmacokinetics in the neonate [Elektronische Daten] [E. Nicolle, P. Devillier, G. Bessard, B. Delanoy, C. Durand] Nalbuphine, a mixed agonist-antagonist opiate, is commonly used as a systemic analgesic during labour. Recent reports of perinatal adverse effects prompted us to carry out therapeutic nalbuphine monitoring in obstetric analgesia. Because data on fetomaternal transfer are scarce and the pharmacokinetics of this drug in the neonate are largely unknown, we report data obtained from 28 parturients treated with nalbuphine either intramuscularly and/or intravenously during labour. Plasma nalbuphine levels were measured by high-performance liquid chromatography (HPLC) with electrochemical detection. At delivery, 30-150 min after maternal administration, nalbuphine concentrations ranged from 5.0 to 79.2 ng·ml−1 in mother plasma samples and from 3.0 to 46.6 ng·ml−1 in umbilical cord plasma samples. Nalbuphine concentrations were highly correlated to dose. The fetomaternal ratio was high: 0.74 and not correlated to the administered dose of nalbuphine. An estimated plasma half-life of 4.1 h was calculated from two determinations in the neonate based on the assumption of a monoexponential decay of nalbuphine concentrations. Apart from a flattening of the fetal heart rate tracing in 54% of the cases, only one neonate had a low Apgar score at birth. The apparent prolonged half-life of nalbuphine in the neonate indicates the usefulness of an intramuscular injection of naloxone to prevent recurrence of cardiorespiratory depression due to nalbuphine administration to the mother. Springer-Verlag, 1996 Nalbuphine nationallicence Neonate nationallicence therapeutic drug monitoring nationallicence placental transfer nationallicence pharmacokinetics nationallicence Nicolle E. Laboratoire de Pharmacologie, Centre Hospitalier Universitaire de Grenoble, BP 217, F-38043, Grenoble Cedex 09, France aut Devillier P. Laboratoire de Pharmacologie, Centre Hospitalier Universitaire de Grenoble, BP 217, F-38043, Grenoble Cedex 09, France aut Bessard G. Laboratoire de Pharmacologie, Centre Hospitalier Universitaire de Grenoble, BP 217, F-38043, Grenoble Cedex 09, France aut Delanoy B. Service de Pédiatrie, Hôpital de St Julien-en-Genevois, France aut Durand C. Service de Pédiatrie, Hôpital de St Julien-en-Genevois, France aut European Journal of Clinical Pharmacology Springer-Verlag 49/6(1996-03-01), 485-489 0031-6970 49:6<485 1996 49 228 https://doi.org/10.1007/BF00195935 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00195935 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Nicolle E. Laboratoire de Pharmacologie, Centre Hospitalier Universitaire de Grenoble, BP 217, F-38043, Grenoble Cedex 09, France aut NATIONALLICENCE 700 1- Devillier P. Laboratoire de Pharmacologie, Centre Hospitalier Universitaire de Grenoble, BP 217, F-38043, Grenoble Cedex 09, France aut NATIONALLICENCE 700 1- Bessard G. Laboratoire de Pharmacologie, Centre Hospitalier Universitaire de Grenoble, BP 217, F-38043, Grenoble Cedex 09, France aut NATIONALLICENCE 700 1- Delanoy B. Service de Pédiatrie, Hôpital de St Julien-en-Genevois, France aut NATIONALLICENCE 700 1- Durand C. Service de Pédiatrie, Hôpital de St Julien-en-Genevois, France aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 49/6(1996-03-01), 485-489 0031-6970 49:6<485 1996 49 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer